YourLawyer.com® 1-800-LAW-INFO (1-800-529-4636)
Injured by Baycol?
Baycol (generic: cerivastatin) was approved in the United States in 1997. Baycol is part of a class of drugs used to lower cholesterol levels called statins. In August 2001, Baycol was pulled from the market. Baycol was withdrawn from the market because it has been linked to Rhabdomyolysis, which caused 31 deaths in the United States.Rhabdomyolysis is a condition that causes muscle-cell breakdown (atrophy) and causes muscle pain, weakness, tenderness, malaise, fever, dark urine, nausea and vomiting. Rhabdomyolysis is a potentially life threatening condition.
"While all statins have been associated with very rare reports of rhabdomyolysis, cases of fatal rhabdomyolysis in association with the use of Baycol have been reported significantly more frequently than for other approved statins," the FDA said.
Rhabdomyolysis involves injuries to the kidneys caused by toxic effects of the contents of muscle cells. Myoglobin is an iron-containing pigment found in the skeletal muscle. When the skeletal muscle is damaged, the myoglobin is released into the bloodstream. It is filtered out of the bloodstream by the kidneys. Myoglobin may occlude the structures of the kidney, causing damage such as acute tubular necrosis or kidney failure. Myoglobin breaks down into potentially toxic compounds, which will also cause kidney failure.
If you or a loved one took Baycol and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney.
BaycolRSS Feed
Bayer's filings with SEC reveal two subpoenas
Mar 8, 2006 | Pittsburgh Post-Gazette
Bayer AG disclosed in filings with the Securities and Exchange Commission that it received subpoenas in two separate cases.The German-based drug and chemicals firm was subpoenaed by the Department of Justice last month in connection with alleged price-fixing of plastics products. Bayer said it was a defendant in multiple class-action lawsuits that have been consolidated in federal court in Kansas.Separately, the company was subpoenaed by the U.S. attorney in New Jersey in connection with an...
Bayer gets second subpoena over withdrawn Baycol drug
Mar 7, 2006 | AP
Bayer AG disclosed Monday that it received a subpoena from the U.S. attorney for New Jersey relating to its withdrawn Baycol/Cerivastatin anti-cholesterol drug, which has allegedly been linked to about 100 deaths.Bayer received the subpoena last month, according to the company's annual report filed with the federal Securities and Exchange Commission.The German-based pharmaceutical and chemical company had received a subpoena in January 2004 also related to its Baycol drug from the Defense...
Bad Day All Around for Bayer with Announcements of $1.1 Billion in Baycol-Related Settlements and the Indictment of Two Former Executives for Price-Fixing
Aug 12, 2005 | www.newsinferno.com
Yesterday, Bayer AG, the German pharmaceutical and chemical giant, had the kind of bad-news day major corporations dread. On the pharmaceutical side, the company announced, that as of June 30, it has paid some $1.138 billion to settle 3,017 personal injury cases worldwide stemming from its ill-fate cholesterol drug, Baycol, which was pulled from the market in 2002 as a result of serious safety problems.The settlements have averaged about $378,000 and the company still faces significant exposure...
Bayer Pays 1.138 Bln Usd to Settle 3,017 Baycol Cases
Aug 10, 2005 | AFX
Bayer AG said that as of June 30 it has paid 1.138 bln usd to settle 3,017 cases worldwide related to its former cholesterol-lowering blockbuster drug Baycol (Lipobay), which was withdrawn from the market three years ago for safety reasons.The chemicals and pharmaceutical hybrid has paid on average 377,195 usd to settle each case.It said there are now 5,986 cases pending compared to 'fewer than 6,000' as announced at the annual general meeting.On May 10, Bayer said it had paid 1.133 bln usd to...
Bayer Pays 1.133 Bln Usd to Settle 2,995 Baycol Cases
May 10, 2005 | AFX
Bayer AG said that as of April 25 it has paid 1.133 bln usd to settle 2,995 cases worldwide related to its former cholesterol-lowering blockbuster drug Baycol (Lipobay), which was withdrawn from the market three years ago for safety reasons.The figures show the chemicals and pharmaceutical hybrid has paid on average 381,224 usd to settle each case.At the annual general meeting in late April, Bayer said there are now fewer than 6,000 Baycol cases pending, compared to 6,174 cases in March.On...
Baycol
Quick Facts
Baycol Reference Guide
Generic Name
Cerivastatin
Date Approved
June 26, 1997
Manufacturer
Bayer Corporation
Status
Removed 2001
Approved Uses
Cholesterol
Serious Side Effects
Rhabdomyolysis
Muscle pain
Dark urination
Myalgia
Related Topics
Crestor
Rhabdomyolysis
Defective Drugs
Diseases
News Feeds
WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS
